Roche makes ADC deal with China’s MediLink Therapeutics for $50M upfront

Antibody-drug conjugates, one of the creams of the crop in 2023 biopharma dealmaking, are riding into 2024 on a strong note as Roche pays $50 million upfront to collaborate with a biotech in China, where many of the ADC deals have been made recently.

The Swiss Big Pharma is pairing…
Click here to view original post

Advertisement — Advertise with Biotech Networks